Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Exubera Launch Now Slated For July

This article was originally published in The Pink Sheet Daily

Executive Summary

The company had previously said that the inhaled insulin would be available in June; it was approved in January.

You may also be interested in...



Exubera Launch Falls Back To Early Autumn

Pfizer will roll out an education program for physicians and patients at the end of July and will launch the inhaled insulin in September.

Exubera Launch Falls Back To Early Autumn

Pfizer will roll out an education program for physicians and patients at the end of July and will launch the inhaled insulin in September.

Exubera Labeling Could Trigger Dosing Errors, ISMP Says

Due to potential confusion between converting doses of inhaled insulin to units of injectable insulin, current labeling and dosing instructions should not have been approved, hazard alert says.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064309

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel